At RBV Capital, we are building a diversified portfolio of early-stage breakthrough assets.
Our investment strategy focuses on innovative science addressing critical unmet medical needs, and relies on selecting strong management teams with a clear vision.
We are interested in biopharmaceuticals, biomedical technology and services, bioinformatics and healthcare IT, and medical device companies.
RBV Capital (backed by Alexey Repik’s R-Pharmand RVC) invested RUB 105 million (ca. $1.5M) in PanDx, a UK-based company developing a novel catheter to treat acute pancreatitis and other severe conditions of the gastrointestinal tract (GI).
Intellogic LLC, raised 160M rubles (ca $2M) in its Series B investment round to further develop its artificial intelligence platform for the analysis of medical images, Botkin.AI.
Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Julie Iwashita as the company’s Vice President of Clinical Operations.
